Treatment interruption is a risk factor for sickness presenteeism: a large-scale cross-sectional study during the COVID-19 pandemic

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported and partly funded by research grants from the University of Occupational and Environmental Health, Japan (no grant number); the Japanese Ministry of Health, Labour and Welfare (grant numbers H30-josei-ippan-002, H30-roudou-ippan-007, 19JA1004, 20JA1006, 210301-1, and 20HB1004); Anshin Zaidan (no grant number); the Collabo-Health Study Group (no grant number); and Hitachi Systems, Ltd. (no grant number); and scholarship donations from Chugai Pharmaceutical Co., Ltd. (no grant number).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Ethics Committee of the University of Occupational and Environmental Health, Japan (Approval No. R2-079 and R3-006).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes